Daniel Wang Email & Phone Number

Shanghai

• Worked as a full-time offshore analyst for a top four U.S. investment bank, supporting China Healthcare Equity Research Team (Ranked top three by Institutional Investor).
• Analyzed companies among different sectors (pharmaceuticals, biologics, TCM, distributors and medical devices) through evaluating macro policies, industry fundamentals, competition landscapes, major products.
• Developed and utilized detailed financial models for the valuation of public and pre-IPO companies, using valuation methods including discounted cash flow method, price earnings multiple valuation and Sum-Of-Parts.
• Created and updated industry databases including healthcare indices, industry data, tender progress, new drugs approvals, price track of APIs and batch release of biotech products.
• Co-wrote 2010 and 2011 China Healthcare Handbook, including in-depth data and analysis on healthcare industry, sub-sectors and hospital drugs sales data, receiving hundreds of client requests from institution investors.
• Compiled marketing materials and assisted in the road shows.

• Performed on-site statutory and IPO audit engagements for four Chinese, three European and two U.S. clients in manufacturing industry.
• Created revenue and profit projection models for IPO audit of China Northern Locomotive and Rolling Stock Industry Corporation.
• Prepared and reviewed financial statements, footnote disclosures and auditor’s reports.
• Evaluated the design and operating effectiveness of internal control systems.